Hyloris Pharmaceuticals SA (FRA:52U)

Germany · Delayed Price · Currency is EUR

5.92

+0.18 (3.14%)

Last updated: Dec 5, 2025, 8:16 AM CET

14.73% (1Y)

Market Cap	168.00M
Revenue (ttm)	8.46M
Net Income (ttm)	-6.41M
Shares Out	n/a
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	581
Average Volume	125
Open	5.92
Previous Close	5.74
Day's Range	5.92 - 5.92
52-Week Range	4.54 - 7.14
Beta	n/a
RSI	53.86
Earnings Date	Mar 26, 2026

About Hyloris Pharmaceuticals

Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortal... [Read more]

Industry Pharmaceutical Preparations

Founded 2012

Employees 49

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 52U

Full Company Profile

Financial Performance

In 2024, Hyloris Pharmaceuticals's revenue was 9.76 million, an increase of 159.64% compared to the previous year's 3.76 million. Losses were -6.34 million, -58.76% less than in 2023.

Financial Statements

News

There is no news available yet.